HSBC Holdings
RXRX icon

HSBC Holdings’s Recursion Pharmaceuticals RXRX Stock Holding History

HSBC Holdings’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$511K Sell
139,386
-107,371
-44% -$357K ﹤0.01% 2270
2026
Q1 		$753K Sell
246,757
-571,559
-70% -$2.21M ﹤0.01% 2008
2025
Q4 		$3.37M Buy
818,316
+689,903
+537% +$3.42M ﹤0.01% 1362
2025
Q3 		$614K Buy
128,413
+111,840
+675% +$587K ﹤0.01% 2000
2025
Q2 		$85.9K Sell
16,573
-20,863
-56% -$102K ﹤0.01% 2873
2025
Q1 		$197K Buy
37,436
+1,097
+3% +$8K ﹤0.01% 2626
2024
Q4 		$249K Buy
36,339
+11,822
+48% +$79.5K ﹤0.01% 2598
2024
Q3 		$164K Sell
24,517
-3,455
-12% -$24.8K ﹤0.01% 2688
2024
Q2 		$206K Buy
27,972
+5,764
+26% +$50.3K ﹤0.01% 2534
2024
Q1 		$221K Buy
+22,208
New +$247K ﹤0.01% 2626
2023
Q3 		– Sell
-19,495
Closed -$148K – 2826
2023
Q2 		$148K Buy
19,495
+9,004
+86% +$63K ﹤0.01% 2384
2023
Q1 		$70.3K Buy
10,491
+290
+3% +$2.3K ﹤0.01% 2542
2022
Q4 		$76.3K Hold
10,201
– – ﹤0.01% 2939
2022
Q3 		$111K Sell
10,201
-2,870
-22% -$29.1K ﹤0.01% 2736
2022
Q2 		$105K Buy
+13,071
New +$87.5K ﹤0.01% 3029

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

HSBC Holdings's RXRX Position: Q2 2026 in Review

HSBC Holdings reduced its Recursion Pharmaceuticals (RXRX) stake by 44% in Q2 2026, selling an estimated $357K and leaving 139,386 shares worth $511K. The position accounts for ﹤0.01% of the portfolio, ranked #2270.

HSBC Holdings first reported a position in RXRX in Q2 2022 and has held it in 15 quarters since. The position peaked at $3.37M in Q4 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • HSBC Holdings held 139,386 shares of Recursion Pharmaceuticals worth $511K as of Q2 2026.
  • HSBC Holdings sold 107,371 Recursion Pharmaceuticals shares in Q2 2026, an estimated $357K.
  • Recursion Pharmaceuticals made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #2270 holding.
  • HSBC Holdings first reported a position in Recursion Pharmaceuticals in Q2 2022 and has held it in 15 quarters since.
  • HSBC Holdings's Recursion Pharmaceuticals position peaked at $3.37M in Q4 2025.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.